Yood MU, Campbell UB, Rothman KJ, Jick SS, Lang J, Wells KE, Jick H, Johnson CC. Using prescription claims data for drugs available over-the-counter (OTC). Pharmacoepidemiol Drug Saf. 2007 Oct 1;16(9):961-8.
Johannes CB, Seeger JD, Koro CE, Cutone JA, Quinn SG. Response to a comment on 'the risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy'. Pharmacoepidemiol Drug Saf. 2007 Oct 1;16(10):1073-4.
Seeger JD, Schneeweiss S, Doherty M, Dey D, Rivero E. Pattern of Visudyne® use among patients enrolled in a US health insurance database. Poster presented at the 23rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management; August 2007. Quebec City, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2007 Aug 20; 16(Suppl 2):S105.
Gilsenan AW, Wang J, Midkiff KD, Andrews EB. Impact of potential selection bias on prevalence estimates of lower urinary tract symptoms in a primary care setting. Presented at the 23rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management; August 21, 2007. Quebec City, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2007 Aug 7; 16(Suppl 2):S55. doi: 10.1002/pds.1461
Mines D, Fireman B, Lee J, Go AS. Venlafaxine use was not associated with an increased risk of sudden cardiac death. Presented at the 23rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2007. Quebec City, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2007 Aug; 16(Suppl 2):S7.
Midkiff K, Johannes CB, Mohan AK. Strengths and limitations of drug abuse warning network data used in a surveillance study. Poster presented at the 23rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 23, 2007. Quebec City, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2007 Aug; 16(S1-274):S234.
Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. Pharmacoepidemiol Drug Saf. 2007 May 1;16(5):504-12.
Varas-Lorenzo C, Maguire A, Castellsague J, Perez-Gutthann S. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level. Pharmacoepidemiol Drug Saf. 2007 Apr 1;16(4):366-76.